Drug development in IBD: from novel target identification to early clinical trials

The Pharmacokinetics of Biologics: A Primer

(2015) Diane R. Mould   DIGESTIVE DISEASES

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease

(2015) Paolo Biancheri et al.   GASTROENTEROLOGY

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

Intestinal Microbiota in Animal Models of Inflammatory Diseases

(2015) G. Hörmannsperger et al.   ILAR JOURNAL

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations

(2015) Jimmy Z Liu et al.   NATURE GENETICS

Immunopathogenesis of IBD: current state of the art

(2015) Heitor S. P. de Souza et al.   Nature Reviews Gastroenterology & Hepatology

Systems biology in inflammatory bowel diseases

(2014) Christos Polytarchou et al.   CURRENT OPINION IN GASTROENTEROLOGY

Integrating Omics: The Future of IBD?

(2014) Claudio Fiocchi   DIGESTIVE DISEASES

Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases

(2014) Silvio Danese et al.   GASTROENTEROLOGY

Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD

(2014) Vicky De Preter et al.   GUT

Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease

(2014) Tim Raine et al.   GUT

Multi-omics analysis of inflammatory bowel disease

(2014) Hu Huang et al.   IMMUNOLOGY LETTERS

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

(2014) Raja Atreya et al.   NATURE MEDICINE

The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases

(2013) Vassilis Valatas et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Animal models of human disease: Inflammation

(2013) David R. Webb   BIOCHEMICAL PHARMACOLOGY

iPOP Goes the World: Integrated Personalized Omics Profiling and the Road toward Improved Health Care

(2013) Jennifer Li-Pook-Than et al.   CHEMISTRY & BIOLOGY

Personalizing medicine for autoimmune and inflammatory diseases

(2013) Andrew C Chan et al.   NATURE IMMUNOLOGY

Murine Models of Inflammatory Bowel Disease (IBD)

(2013) Jason DeVoss et al.   TOXICOLOGIC PATHOLOGY

Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations

(2012) Núria Planell et al.   GUT

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Microbial and Histopathologic Considerations in the Use of Mouse Models of Inflammatory Bowel Diseases

(2012) Trenton R. Schoeb et al.   INFLAMMATORY BOWEL DISEASES

Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks

(2012) Martina Perše et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state

(2012) C. Polytarchou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New therapies for inflammatory bowel disease: from the bench to the bedside

(2011) Silvio Danese   GUT

Animal models of IBD: linkage to human disease

(2010) Atsushi Mizoguchi et al.   CURRENT OPINION IN PHARMACOLOGY

A human gut microbial gene catalogue established by metagenomic sequencing

(2010) Junjie Qin et al.   NATURE

Network medicine: a network-based approach to human disease

(2010) Albert-László Barabási et al.   NATURE REVIEWS GENETICS

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Late Crohn’s disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients

(2009) M. VENY et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation

(2009) Dimitrios Iliopoulos et al.   CELL

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Molecular networks as sensors and drivers of common human diseases

(2009) Eric E. Schadt   NATURE

Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease

(2008) Silvia Melgar et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Nonimmune cells in inflammatory bowel disease: from victim to villain

(2008) Silvio Danese   TRENDS IN IMMUNOLOGY